Brazikumab (MEDI2070): A Comprehensive Monograph on a Discontinued Interleukin-23 Inhibitor for Inflammatory Bowel Disease

Executive Summary

Brazikumab (MEDI2070, AMG 139) was a fully human monoclonal antibody representing a promising second-generation therapeutic agent designed to treat autoimmune conditions, with a primary focus on inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC). As a highly specific inhibitor of the p19 subunit of interleukin-23 (IL-23), Brazikumab embodied a targeted immunomodulatory strategy aimed at overcoming the limitations of earlier, less specific biologics. Clinical investigations, particularly a long-term Phase 2a study in patients with moderate-to-severe CD, demonstrated that the drug was well-tolerated, possessing an acceptable safety profile over a 100-week period with no major adverse cardiac events, malignancies, or deaths reported. Early efficacy signals were also positive, suggesting a tangible clinical benefit in a difficult-to-treat patient population.

Despite this sound scientific and clinical foundation, the development of Brazikumab was ultimately terminated. This report provides a comprehensive analysis of the drug's entire lifecycle, concluding that its failure was not a result of clinical or scientific shortcomings but rather a consequence of a confluence of strategic, logistical, and commercial challenges. The narrative of Brazikumab is dominated by a convoluted corporate history, which saw its development rights transferred from Amgen to AstraZeneca, then licensed to Allergan, and finally returned to AstraZeneca as a mandated divestiture during AbbVie's acquisition of Allergan. This regulatory intervention, driven by antitrust concerns, created a complex and ultimately unsustainable development and funding arrangement.

Compounding this corporate instability, the drug's late-stage clinical programs were beset by significant, insurmountable delays stemming from global events, including the COVID-19 pandemic and the war in Ukraine. These disruptions pushed the projected market entry years beyond its original target, by which time the competitive landscape for IL-23 inhibitors had matured and become crowded with formidable, already-marketed competitors. Faced with a protracted timeline, the cessation of co-funding from AbbVie, and a diminished commercial opportunity, AstraZeneca made the strategic decision in June 2023 to discontinue the program. Brazikumab thus serves as a critical case study in modern biopharmaceutical development, illustrating how a therapeutically viable candidate with a favorable safety profile can be defeated by the overwhelming pressures of market timing, operational execution, and the profound ripple effects of large-scale corporate mergers and acquisitions.

Molecular Profile and Mechanism of Action

The therapeutic rationale for Brazikumab is rooted in its precise molecular design and its targeted intervention in a key inflammatory pathway. Its classification, target specificity, and the downstream immunological consequences of its action define its position as a second-generation biologic agent for autoimmune diseases.

Drug Identification and Classification

Brazikumab is a biologic, or biotech, therapeutic agent, specifically classified as a fully human Immunoglobulin G2 ($IgG_2$) monoclonal antibody.[1] As an investigational drug, it was assigned several identifiers throughout its development. The International Nonproprietary Name (INN) is Brazikumab, and it is registered with DrugBank Accession Number DB16115 and CAS Number 1610353-18-8.[3] Its primary development codes were MEDI2070 and AMG 139, reflecting its origins with MedImmune/AstraZeneca and Amgen, respectively.[5] The molecular formula for this large protein is $C_{6410}H_{9830}N_{1718}O_{2016}S_{50}$, with a corresponding molar mass of approximately 144820.16 g·mol−1.[4] Therapeutically, it is categorized as an anti-inflammatory agent intended for the treatment of immune system and digestive system disorders.[6]

Attribute	Value	Source(s)
Generic Name	Brazikumab	3
DrugBank ID	DB16115	3
Type	Biotech	3
CAS Number	1610353-18-8	4
Development Codes	MEDI2070, AMG 139	5
Molecular Formula	$C_{6410}H_{9830}N_{1718}O_{2016}S_{50}$	4
Molar Mass	144820.16 g·mol−1	4
Compound Class	Monoclonal Antibody ($IgG_2$)	1
Target	Interleukin-23 (IL-23)	4
Mechanism of Action	IL-23 p19 Subunit Inhibitor	6

Target and Binding: The IL-23/p19 Axis

The molecular target of Brazikumab is Interleukin-23 (IL-23), a heterodimeric cytokine that plays a pivotal role in promoting and sustaining pro-inflammatory immune responses.[1] IL-23 is considered a key driver in the pathogenesis of numerous autoimmune and inflammatory diseases, including Crohn's disease, ulcerative colitis, and psoriasis.[5] The cytokine is composed of two distinct subunits: p40 and p19. The p40 subunit is also a component of another important cytokine, IL-12, which is involved in different immunological functions, including host defense.[1]

Brazikumab was engineered to achieve high specificity by selectively binding to the p19 subunit (also known as IL23A), which is unique to the IL-23 cytokine.[1] This design feature is the defining characteristic of the second generation of IL-23 pathway inhibitors. By targeting the p19 subunit, Brazikumab was intended to neutralize the pro-inflammatory effects of IL-23 without interfering with the functions of IL-12. This contrasts with first-generation therapies, such as ustekinumab, which target the shared p40 subunit and therefore inhibit both IL-12 and IL-23 signaling.[1] The hypothesis underlying this targeted approach was that specific inhibition of IL-23 would provide a more focused therapeutic effect for IBD while potentially offering an improved safety profile by leaving the IL-12 pathway intact.[9]

The mechanism of action is one of direct, competitive inhibition. By binding with high affinity to the p19 subunit of circulating IL-23, Brazikumab physically obstructs the cytokine, preventing it from docking with its cell surface receptor complex.[8] This blockade is the initiating event that disrupts the entire downstream signaling cascade.

Downstream Signaling Cascade Inhibition

The IL-23 receptor, expressed on the surface of target immune cells, is composed of the IL-12Rβ1 and IL-23R subunits. The intracellular domains of this receptor complex are associated with members of the Janus kinase (JAK) family of enzymes, specifically Tyrosine kinase 2 (Tyk2) and Janus kinase 2 (Jak2).[8] Upon successful binding of IL-23 to its receptor, these JAK enzymes become activated and phosphorylate tyrosine residues on the receptor's intracellular domain.

This phosphorylation creates docking sites for latent cytoplasmic transcription factors known as Signal Transducer and Activator of Transcription (STAT) proteins, primarily STAT3 in the case of IL-23 signaling.[8] Once recruited to the receptor, STAT3 monomers are themselves phosphorylated by the activated JAKs. This phosphorylation event triggers the STAT3 monomers to detach from the receptor, form homodimers, and translocate from the cytoplasm into the cell nucleus. Inside the nucleus, the STAT3 dimer binds to specific promoter regions of target genes, initiating the transcription of a host of pro-inflammatory proteins.[8]

Brazikumab's action at the very beginning of this pathway—blocking the IL-23/receptor interaction—prevents the initial activation of Jak2 and Tyk2. Consequently, the entire JAK-STAT signaling cascade is arrested before it can begin. This effectively silences the IL-23-mediated genetic program that drives chronic inflammation.[8]

Immunological Consequences

The ultimate therapeutic goal of Brazikumab is achieved through the functional consequences of this signaling blockade on key immune cell populations. IL-23 is a master regulator responsible for the maintenance, expansion, and pathogenic function of several cell types, most notably T helper 17 (Th17) cells.[1] Th17 cells are a major source of inflammatory mediators in the gut mucosa of IBD patients. IL-23 also acts on other immune cells, including natural killer (NK) cells, innate lymphoid cells (ILCs), and γ/δ T cells.[5]

By inhibiting IL-23 signaling, Brazikumab was expected to suppress the activity of these cell populations.[5] This suppression leads to a marked reduction in the production and release of a suite of potent pro-inflammatory cytokines that are the direct effectors of tissue damage in IBD. These downstream cytokines include IL-17, IL-22, Tumor Necrosis Factor-alpha (TNFα), and Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF).[5] By attenuating this pro-inflammatory milieu, Brazikumab was designed to break the cycle of chronic inflammation, reduce inflammatory infiltration in the intestinal wall, promote mucosal healing, and thereby ameliorate the clinical signs and symptoms of Crohn's disease and ulcerative colitis.

Clinical Development Program

The clinical development of Brazikumab was a comprehensive and ambitious endeavor that spanned multiple phases and indications before its eventual termination. The program was designed to establish its safety and efficacy in key autoimmune diseases, with a strategic focus on inflammatory bowel disease.

Overview of Investigated Indications

The primary therapeutic area for Brazikumab's clinical development was Inflammatory Bowel Disease (IBD), with dedicated, large-scale programs for both moderate-to-severe Crohn's Disease (CD) and Ulcerative Colitis (UC).[10] These conditions represented a significant unmet medical need, as a substantial portion of patients either do not respond to or lose response to existing therapies, including anti-TNFα agents.[1] The program also included an early exploratory investigation into moderate to severe Psoriasis, another IL-23-mediated disease. However, after the completion of a Phase 1 study, development for this indication was not pursued further.[5]

NCT Identifier	Trial Name/Acronym	Phase	Indication(s)	Key Design Features	Status	Source(s)
NCT01094093	N/A	1	Psoriasis, Healthy Volunteers	Safety, Tolerability, PK/PD	Completed	5
NCT01258205	N/A	1	Crohn's Disease, Healthy Volunteers	Multiple Ascending Doses	Completed	5
NCT01714726	N/A	2a	Crohn's Disease	Double-blind induction; 100-week open-label extension	Completed	1
NCT03759288	INTREPID Lead-In	2b/3	Crohn's Disease	Seamless design; Placebo and Adalimumab comparators	Terminated	3
NCT03961815	INTREPID OLE	3	Crohn's Disease	Open-label extension for NCT03759288	Terminated	15
NCT03616821	EXPEDITION Lead-in	2	Ulcerative Colitis	Placebo-controlled; Vedolizumab comparator in program	Terminated	10
D5272C00002	EXPEDITION OLE	2	Ulcerative Colitis	Open-label extension for NCT03616821	Terminated	6

Phase I and IIa Studies (Foundation Building)

The foundational work for Brazikumab's clinical program was established through a series of early-phase trials designed to assess its fundamental properties in humans.

• NCT01094093: This was a Phase 1 study that provided the first human data on the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of Brazikumab. The trial enrolled both healthy volunteers and patients with moderate to severe psoriasis, an indication that provided a clear biological rationale for IL-23 inhibition.[5]
• NCT01258205: Following the initial single-dose study, this Phase 1 trial evaluated multiple ascending doses of Brazikumab in healthy subjects and in patients with mild to severe Crohn's disease. This study was critical for determining an appropriate dosing range for subsequent efficacy trials.[5]
• NCT01714726: This was the pivotal Phase 2a study that provided the strongest proof-of-concept for Brazikumab in IBD. It was designed to evaluate the efficacy and safety of the drug in patients with active, moderate-to-severe CD who had previously failed or were intolerant to anti-TNFα therapy—a challenging patient population.[1] The study consisted of a 12-week double-blind induction period, which demonstrated a positive efficacy signal, followed by a 100-week open-label extension period. This extension became the primary source of the robust long-term safety and tolerability data available for the drug.[1]

Pivotal Late-Stage Programs (The INTREPID and EXPEDITION Trials)

Based on the promising results from the Phase 2a study, two large, ambitious, late-stage programs were initiated to definitively establish the efficacy and safety of Brazikumab for regulatory submission.

INTREPID Program (Crohn's Disease)

The INTREPID program was designed to be the definitive evaluation of Brazikumab in Crohn's disease.

• NCT03759288 (INTREPID Lead-In): This trial was the centerpiece of the CD program. It was structured as an "operationally seamless" Phase IIb/III study, a modern trial design intended to accelerate development by combining the dose-ranging stage (Phase IIb) with the confirmatory stage (Phase III) into a single protocol.[14] The study was a multicenter, randomized, double-blind, parallel-group trial in participants with moderately to severely active CD.[14] A key feature of its design was the inclusion of both a placebo arm and an active-comparator arm using adalimumab (Humira®), a leading anti-TNFα therapy.[13] This design was highly ambitious, as it aimed not only to demonstrate superiority over placebo but also to generate comparative data against a well-established standard of care. The planned primary endpoint was the proportion of patients achieving clinical remission, defined by a Crohn's Disease Activity Index (CDAI) score of less than 150, at Week 12.[14]
• NCT03961815 (INTREPID OLE): This was the accompanying open-label extension (OLE) study. Participants who completed the INTREPID lead-in trial were eligible to enroll in the OLE to receive open-label Brazikumab, allowing for the collection of crucial long-term safety and durability of response data.[15]
• Status: Both the lead-in and the OLE studies were ultimately terminated prematurely following AstraZeneca's strategic decision in June 2023 to discontinue the entire IBD development program.[3]

EXPEDITION Program (Ulcerative Colitis)

Running in parallel to the INTREPID program, the EXPEDITION program was designed to evaluate Brazikumab in ulcerative colitis.

• NCT03616821 (EXPEDITION Lead-in): This was a Phase II, multicenter, randomized, double-blind, placebo-controlled study in participants with moderately to severely active UC.[17] The primary goal was to assess the efficacy and safety of Brazikumab in inducing clinical and endoscopic improvement. Key inclusion criteria for this study were based on the Modified Mayo Score (mMS), requiring evidence of active disease based on stool frequency, rectal bleeding, and endoscopic appearance.[17] While the lead-in study was placebo-controlled, the broader program design also included plans for comparison against vedolizumab (Entyvio®), an integrin inhibitor used in UC.[2]
• D5272C00002 (EXPEDITION OLE): This was the open-label extension study for the EXPEDITION program, serving the same purpose as its INTREPID counterpart: to gather long-term safety and efficacy data for patients with UC.[18]
• Status: Similar to the CD program, the entire EXPEDITION program, including its OLE, was terminated. The clinical trial record for the OLE study provides a notable addendum: due to the early termination, data cleaning proved challenging, and as a result, the databases were locked with unclean data, and the majority of planned analyses were not performed, with efforts focused only on key safety variables.[18]

The ambitious designs of these late-stage trials, particularly the seamless Phase IIb/III structure and the inclusion of active comparators, reflect the high degree of confidence the developers had in Brazikumab's potential. However, the complexity and global scale of these studies also rendered them highly vulnerable to the widespread operational disruptions that ultimately contributed to the program's demise. A simpler, more focused development plan might have been more resilient to the external pressures that emerged, but the chosen path was one of aggressive, accelerated development against established standards of care, a high-risk, high-reward strategy that was ultimately undone by factors beyond the drug's clinical performance.

Synthesis of Clinical Efficacy and Safety Data

The clinical data available for Brazikumab, though incomplete due to the premature termination of its late-stage programs, provides a valuable profile of the drug's performance. The evidence points towards a promising, though not definitively superior, efficacy signal and, more significantly, a robust and reassuring long-term safety profile. This disconnect between the drug's acceptable clinical characteristics and its ultimate discontinuation is a central theme of its development story.

Efficacy in Crohn's Disease

The most substantive efficacy data for Brazikumab in Crohn's disease comes from the completed Phase 2a study (NCT01714726).

• Phase 2a Results: In this study, which enrolled patients with moderate-to-severe CD who had already failed or were intolerant to anti-TNFα therapy, treatment with Brazikumab resulted in a demonstrable clinical improvement after 8 weeks.[1] This improvement was measured by a clinical response, defined as a decrease in the Crohn's Disease Activity Index (CDAI), a composite score that measures disease symptoms and severity.[1] This finding was critical as it provided the initial proof-of-concept in a difficult-to-treat, post-TNF patient population, justifying the progression to more extensive Phase III studies.
• Late-Stage Data: The pivotal Phase IIb/III INTREPID trial was designed to provide definitive efficacy data, with a primary endpoint of CDAI remission (score < 150) at week 12.[14] However, due to the trial's termination, a complete dataset for this primary endpoint was never generated or reported, leaving the ultimate efficacy of Brazikumab in CD unconfirmed in a large-scale setting.
• Competitive Context: An analysis of the competitive landscape based on available Phase II data raised some questions about Brazikumab's relative potency. Indirect, cross-trial comparisons suggested that the clinical remission rate delta for Brazikumab versus placebo at 8 weeks (27.1%) might be numerically lower than that observed for its direct competitors, mirikizumab (40.6% at 12 weeks) and risankizumab (37% at 12 weeks).[24] While such comparisons are inherently flawed due to differences in trial populations, designs, and assessment time points, these early figures may have factored into the strategic assessment of Brazikumab's ability to compete in a crowded market, contributing to the "evolving competitive landscape" cited as a reason for its discontinuation.[10]

Efficacy in Ulcerative Colitis

The clinical efficacy of Brazikumab in ulcerative colitis is largely unknown. The Phase II EXPEDITION program was terminated before mature data could be collected and analyzed. The official record for the open-label extension study explicitly states that because of the early termination, "the majority of planned analyses were not performed".[18] This lack of data means that no definitive conclusions can be drawn regarding Brazikumab's potential as a treatment for UC.

Long-Term Safety and Tolerability Profile

In stark contrast to the incomplete efficacy picture, the long-term safety and tolerability data for Brazikumab is the most robust and compelling aspect of its clinical profile. This information is derived primarily from the 100-week open-label period of the Phase 2a study (NCT01714726), which followed 104 patients with moderate-to-severe CD.[1]

• Overall Adverse Events: Over the 100-week period, 83.7% of patients experienced at least one treatment-emergent adverse event (TEAE). The vast majority of these events were mild-to-moderate in severity, and the incidence was similar between patients who were continuously on Brazikumab and those who switched from placebo to Brazikumab in the open-label phase.[1]
• Common TEAEs: The most frequently reported TEAEs were consistent with those seen in IBD populations and with other biologics. These included nasopharyngitis (22.1%), headache (22.1%), abdominal pain (18.3%), and exacerbation of Crohn's disease (16.3%).[1]
• Serious Adverse Events: Treatment-emergent serious adverse events (TESAEs) were reported in 19.2% of patients over the two-year period, with a similar incidence between the study groups.[1]
• Infections: The rate of infections, a key concern for immunomodulatory drugs, was manageable. Approximately half of the patients in the continuous Brazikumab group experienced an infection during the study.[1] Importantly, there were only five serious infections, and none were classified as opportunistic infections, which are a particular concern with broader immunosuppressants.[1]
• Discontinuation Rates: Over the 100-week period, 45.2% of patients discontinued the study. The reasons were varied and not solely driven by safety issues. Lack of response was the most common reason (14.4%), followed by patient decision (12.5%), and then TEAEs (11.5%).[1]
• Absence of Critical Safety Signals: The most significant finding from the long-term safety data was the absence of major safety concerns that have plagued other drug classes. Specifically, no major adverse cardiac events (MACE), no malignancies, and no deaths were reported during the 100-week study.[1] This clean safety profile was a major asset for the drug and was explicitly highlighted by AstraZeneca in its official statement announcing the program's discontinuation, which noted that "No safety concerns were identified for patients in these trials".[10]

This strong safety evidence creates a compelling paradox. In an industry where late-stage drug development is frequently derailed by unexpected safety signals, Brazikumab appeared to have a favorable benefit-risk profile. The fact that a drug with such a reassuring long-term safety record was ultimately abandoned underscores that its failure was not driven by the clinical data itself. It demonstrates that a positive safety profile, while essential, is not sufficient to guarantee a drug's path to market in the face of overwhelming strategic and operational headwinds.

Safety Endpoint	Placebo/Brazikumab Group (n=52) %	Brazikumab/Brazikumab Group (n=52) %	Total (N=104) %
Patients with ≥1 TEAE	84.6	82.7	83.7
Patients with ≥1 TESAE	15.4	23.1	19.2
TEAEs Leading to Discontinuation	9.6	13.5	11.5
Common TEAEs (≥10% Total)
Nasopharyngitis	15.4	28.8	22.1
Headache	23.1	21.2	22.1
Abdominal Pain	17.3	19.2	18.3
Crohn's Disease	11.5	21.2	16.3
Diarrhea	13.5	13.5	13.5
Influenza	15.4	9.6	12.5
Infections	40.4	50.0	45.2 (approx.)
Major Adverse Cardiac Events (MACE)	0	0	0
Malignancies	0	0	0
Deaths	0	0	0

Data derived from the 100-week open-label period of the Phase 2a study (NCT01714726).[1]

Pharmacokinetics, Pharmacodynamics, and Biomarker Research

The characterization of Brazikumab extended beyond efficacy and safety to include a detailed understanding of its behavior within the human body (pharmacokinetics), its biological effects (pharmacodynamics), and innovative research into predicting patient responses through biomarkers.

Pharmacokinetic (PK) Profile

The pharmacokinetic profile of Brazikumab was evaluated to establish appropriate dosing regimens and to understand its absorption, distribution, and elimination.

• Administration and Dosing: The clinical program was designed around a standard biologic administration strategy, utilizing an intravenous (IV) infusion for initial induction dosing to achieve rapid therapeutic concentrations, followed by subcutaneous (SC) injections for long-term maintenance dosing, which is more convenient for patients.[18] A common maintenance dose evaluated in trials was 210 mg administered subcutaneously every 4 weeks.[1]
• Dedicated PK Study (NCT05033431): A formal Phase 1, open-label, parallel-group study was conducted specifically to characterize the single-dose pharmacokinetics, safety, and tolerability of Brazikumab.[27] This study was notable for its inclusion of both healthy Chinese and White participants to assess any potential ethnic differences in drug handling.[27] The study measured a comprehensive set of standard PK parameters, including maximum observed serum concentration ($C_{max}$), area under the serum concentration-time curve from zero to the last quantifiable concentration ($AUC_{last}$), area under the curve from zero to infinity ($AUC_{inf}$), time to reach maximum concentration ($t_{max}$), and the terminal elimination half-life ($t_{1/2λz}$).[27]
• PK Results: The results from the NCT05033431 study provided clear data on the drug's exposure following both IV and SC administration.[29] For instance, a high SC dose resulted in a geometric mean $C_{max}$ of approximately 25,510 to 26,370 ng/mL. The geometric mean $AUC_{inf}$ for SC doses ranged from approximately 23,710,000 to 31,010,000 h*ng/mL. The data indicated that there were no clinically significant differences in pharmacokinetic exposure between the Chinese and White participant cohorts, supporting the use of a consistent dosing strategy across these populations.[29]

Parameter	Administration Route & Dose	Population	Geometric Mean Value	Geometric CV%
$C_{max}$ (ng/mL)	SC Dose 2	Chinese	25510	49.81
	SC Dose 2	White	26370	27.30
	IV Dose 4	Chinese	634200	53.87
	IV Dose 4	White	623800	21.71
$AUC_{inf}$ (h*ng/mL)	SC Dose 2	Chinese	23710000	35.56
	SC Dose 2	White	31010000	16.28
	IV Dose 4	Chinese	214400000	20.56
	IV Dose 4	White	228700000	15.52
$AUC_{last}$ (h*ng/mL)	SC Dose 2	Chinese	22880000	34.72
	SC Dose 2	White	25710000	39.01
	IV Dose 4	Chinese	210200000	20.68
	IV Dose 4	White	220600000	14.73

Data from healthy volunteers in study NCT05033431.[29] "SC Dose 2" and "IV Dose 4" refer to specific dose levels within the study protocol.

Immunogenicity

As with all therapeutic proteins, the potential for the body to develop an immune response against the drug itself (immunogenicity) was a key safety assessment. The clinical development program for Brazikumab included routine monitoring for the incidence of anti-drug antibodies (ADAs) in patient serum.[1] The development of high-titer neutralizing ADAs can potentially reduce a drug's efficacy or, in rare cases, lead to adverse events. While immunogenicity was assessed, specific rates and their clinical impact from the terminated trials have not been published in detail.

Pharmacometric Modeling and Predictive Biomarkers

A particularly innovative aspect of the Brazikumab development program was its investment in pharmacometric modeling to identify biomarkers that could predict patient response.[30] This research represented a move towards precision medicine in IBD, a field where treatment outcomes are notoriously heterogeneous and difficult to predict.

• Identified Biomarkers: The modeling studies revealed that the therapeutic effect of Brazikumab was significantly correlated with the baseline serum levels of two key biomarkers: Interleukin-22 (IL-22) and C-reactive protein (CRP).[7] IL-22 is a cytokine produced downstream of IL-23 activation, and CRP is a well-known systemic marker of inflammation.
• Predictive Value: The analysis predicted a maximal inhibition of disease activity (measured by CDAI) of over 50% in patients with extremely high baseline levels of IL-22 or CRP. In contrast, for patients with very low baseline levels of these biomarkers, the predicted inhibition was only around 20%, a level not substantially different from the placebo effect.[30]
• Clinical Application: These findings had direct clinical implications. They suggested that patients with high inflammatory burden, as indicated by high baseline IL-22 or CRP, were the most likely to derive significant benefit from Brazikumab. Conversely, patients with low levels of these biomarkers might be better candidates for alternative therapies.[30] This research formed the basis for the development of a companion diagnostic test, which was an integral part of the overall program strategy, aimed at selecting the patient population most likely to respond.[13]

The discontinuation of the Brazikumab program represents a significant setback for this precision medicine approach in IBD. The research provided a clear, data-driven framework for personalizing therapy, potentially sparing non-responders from ineffective treatment and maximizing therapeutic benefit for a targeted subpopulation. This sophisticated strategy, which could have been a key differentiator for Brazikumab, was abandoned along with the drug itself, representing a lost opportunity to advance a more personalized standard of care in gastroenterology.

Corporate Development, Regulatory Path, and Discontinuation

The trajectory of Brazikumab was profoundly shaped by a series of complex corporate maneuvers, regulatory interventions, and strategic decisions that ultimately superseded its clinical and scientific merits. Its history is a case study in how external business and logistical factors can determine the fate of an investigational drug.

A Complex Development and Ownership History

Brazikumab's ownership and development responsibilities changed hands multiple times, creating a convoluted and ultimately unstable path forward.

• Origination: The molecule was originally developed by Amgen and its subsidiary MedImmune, which was acquired by AstraZeneca.[4]
• AstraZeneca's Initial Role: Through a 2012 collaboration with Amgen, AstraZeneca took on a central role in developing a portfolio of inflammation assets, including Brazikumab.[13]
• Out-Licensing to Allergan: In 2016, AstraZeneca made a strategic decision to out-license the global rights for Brazikumab to Allergan. At the time, AstraZeneca was focusing its R&D efforts on other core therapy areas, and IBD was considered outside that focus.[12] Allergan then took over the late-stage development, initiating the large INTREPID and EXPEDITION programs.[32]
• The AbbVie-Allergan Merger and Forced Divestiture: The most pivotal event in Brazikumab's history occurred in 2020. AbbVie moved to acquire Allergan in a multi-billion dollar deal. However, this created a significant antitrust issue. AbbVie was already marketing and developing its own highly successful IL-23 inhibitor, risankizumab (Skyrizi), for the same indications as Brazikumab. Regulators in both the United States (Federal Trade Commission, FTC) and Europe (European Commission) concluded that allowing a single company to control two of the very few late-stage, next-generation IL-23 inhibitors would eliminate crucial future competition and harm consumers.[31]
• Return to AstraZeneca: To secure approval for the merger, AbbVie and Allergan were compelled to divest Brazikumab. In May 2020, the global rights were officially returned to AstraZeneca.[13] The terms of this divestiture were unusual: Allergan (now part of AbbVie) was required to fund the ongoing development costs for Brazikumab in CD and UC up to an agreed-upon amount.[10] This created an awkward situation where AbbVie was contractually obligated to finance the development of a direct competitor to its own flagship product, Skyrizi.

Regulatory Interactions and Status

Throughout its development, Brazikumab remained an investigational drug and never achieved marketing approval from any major regulatory agency.

• United States (FDA): The drug's clinical trials were conducted under the oversight of the U.S. Food and Drug Administration. However, the most significant regulatory interaction was indirect, stemming from the FTC's antitrust review.[33] The FTC's complaint explicitly stated that the AbbVie-Allergan merger would eliminate future direct competition in the IL-23 inhibitor market, leading to the consent agreement that required the divestiture of Brazikumab to AstraZeneca.[34] No Biologics License Application (BLA) was ever submitted to the FDA for Brazikumab.
• European Union (EMA): The European Commission mirrored the FTC's concerns, making its approval of the AbbVie-Allergan merger conditional on the divestiture of Brazikumab to preserve competition in the European market.[31] Prior to these events, the program was proceeding along a standard regulatory pathway with the European Medicines Agency. In 2017, the EMA had agreed to a Paediatric Investigation Plan (PIP) for Brazikumab for the treatment of Crohn's disease and ulcerative colitis, a required step for any new medicine seeking approval in Europe.[35]
• Australia (TGA): There is no information in the available records of any specific regulatory filings or interactions with Australia's Therapeutic Goods Administration (TGA) regarding Brazikumab.[12]

Analysis of Program Discontinuation

The culmination of Brazikumab's tumultuous journey was its formal discontinuation.

• Official Announcement: On June 1, 2023, AstraZeneca publicly announced that it was stopping the entire IBD development program for Brazikumab, including the INTREPID and EXPEDITION trials and their open-label extensions.[10]
• Stated Rationale: The company's official reason was twofold: a review of the drug's development timeline and the context of an evolving competitive landscape.[10] AstraZeneca stated that the timeline had been "impacted by delays that could not be mitigated following global events".[10]
• Underlying Factors:

1. Operational Delays: The "global events" referenced were the COVID-19 pandemic and the subsequent Russian invasion of Ukraine. These events severely disrupted global clinical trial operations, including patient recruitment and site management. The INTREPID trial, for example, had numerous research sites in Ukraine.[38] These disruptions caused catastrophic delays; the estimated primary completion date for the INTREPID trial slipped by five years, from 2022 to 2027.[38]
2. Competitive Landscape: In the time lost to these delays, the market for IBD treatments, and specifically for IL-23 inhibitors, did not stand still. Competitors like AbbVie's Skyrizi and Eli Lilly's mirikizumab advanced through their own clinical programs and toward regulatory approval.[24] By the time Brazikumab could have reached the market in the late 2020s, it would have been the third or fourth entrant in its specific class, facing entrenched competitors with established market share and physician familiarity.[24]
3. Financial Pressures: The discontinuation announcement directly coincided with the cessation of funding from AbbVie.[10] With the development timeline massively extended and the commercial prospects diminished, AstraZeneca was faced with the choice of either shouldering the full, substantial cost of completing the late-stage trials for a late-to-market asset or cutting its losses. The company chose the latter.

The sequence of events reveals a clear causal chain. The AbbVie-Allergan merger and the resulting antitrust-mandated divestiture placed Brazikumab back in the hands of a parent company (AstraZeneca) under a precarious funding model. When unprecedented global events crippled the operational execution of its pivotal trials, the drug lost its most valuable asset: time. This loss of time allowed the competitive landscape to shift irrevocably against it, which in turn eroded its commercial viability to the point where continued investment was no longer strategically justifiable.

Competitive Landscape and Concluding Analysis

The decision to terminate the Brazikumab program cannot be fully understood without placing the drug within the context of its therapeutic class and the rapidly evolving market for IBD biologics. Its scientific promise was ultimately overshadowed by the commercial realities of a crowded and competitive field.

Positioning within the IL-23 Inhibitor Class

The therapeutic landscape for IBD has been transformed by biologics targeting the IL-12/23 pathway. Brazikumab was part of a distinct second wave of innovation in this space.

• First vs. Second Generation: The first generation of this class is represented by ustekinumab (Stelara), which targets the p40 subunit common to both IL-12 and IL-23, thus providing dual cytokine inhibition.[1] Brazikumab, along with its direct contemporaries, belongs to the second generation of these therapies. These agents were specifically designed to target only the p19 subunit, unique to IL-23.[1] This specificity was intended to provide more targeted efficacy in IBD with a potentially more favorable safety profile by not interfering with IL-12's role in host defense.[9]
• Direct Competitors: The key direct competitors for Brazikumab were other second-generation, p19-specific monoclonal antibodies. This includes risankizumab (Skyrizi) from AbbVie, guselkumab (Tremfya) from Janssen, and mirikizumab (Omvoh) from Eli Lilly.[9] These drugs represent the cutting edge of IBD therapy and were progressing through clinical development and regulatory review on a faster timeline than the delayed Brazikumab.
• Competitive Differentiation: Within this class, differentiation is based on several factors. Head-to-head clinical trials, such as the SEQUENCE trial comparing risankizumab to ustekinumab, have suggested that the second-generation p19 inhibitors may offer superior efficacy on stringent endpoints like endoscopic remission.[9] Furthermore, practical considerations like administration route (IV vs. SC induction) and dosing frequency for maintenance therapy (e.g., every 4, 8, or 12 weeks) are critical competitive factors influencing both physician and patient preference.[9] The significant delays to Brazikumab's development meant it would have entered a market where these competitors had already established their clinical profiles, secured reimbursement, and built a strong presence among gastroenterologists.

Drug Name (Brand)	Company	Target Subunit	Generation	Key Approved IBD Indications	Maintenance Dosing Frequency
Ustekinumab (Stelara)	Janssen	p40 (IL-12/23)	1st	Crohn's Disease, Ulcerative Colitis	Every 8 or 12 weeks
Risankizumab (Skyrizi)	AbbVie	p19 (IL-23)	2nd	Crohn's Disease	Every 8 weeks
Guselkumab (Tremfya)	Janssen	p19 (IL-23)	2nd	Crohn's Disease	Every 4 or 8 weeks
Mirikizumab (Omvoh)	Eli Lilly	p19 (IL-23)	2nd	Ulcerative Colitis	Every 4 weeks
Brazikumab	AstraZeneca	p19 (IL-23)	2nd	Discontinued (was in development for CD, UC)	N/A (was testing every 4 weeks)

Information compiled from.[1] Approved indications and dosing are subject to change and may vary by region.

Final Assessment: A Case Study in Strategic Failure

The comprehensive analysis of Brazikumab's journey from promising molecule to discontinued program leads to an unequivocal conclusion: this was a failure of strategy and circumstance, not of science. The drug itself, based on available data, was a valid therapeutic candidate. It possessed a highly specific and rational mechanism of action, demonstrated early efficacy signals, and, most importantly, had a reassuring long-term safety profile devoid of the major concerns that often terminate drug development.

Its downfall was orchestrated by a "perfect storm" of non-clinical factors that proved insurmountable:

1. Corporate Instability: A convoluted ownership history created a lack of consistent, long-term strategic stewardship.
2. Market Consolidation: The AbbVie-Allergan merger, a pivotal event in the pharmaceutical industry, inadvertently placed Brazikumab in direct conflict with a future parent company's strategic interests.
3. Regulatory Intervention: Necessary antitrust actions by the FTC and European Commission, while protecting market competition, forced a divestiture that resulted in a fragile and ultimately unsustainable funding arrangement.
4. Operational Catastrophe: Unprecedented global events, namely the COVID-19 pandemic and the war in Ukraine, inflicted critical and irrecoverable delays on the drug's pivotal clinical trials.
5. Competitive Erosion: The time lost to these delays allowed the competitive landscape to mature, transforming Brazikumab from a potential market leader or fast-follower into a distant late entrant with a severely diminished commercial outlook.

The story of Brazikumab serves as a powerful and cautionary tale in modern biopharmaceutical development. It demonstrates with stark clarity that promising science and a clean clinical profile are necessary but insufficient conditions for success. The immense complexities of global trial execution, the far-reaching consequences of corporate mergers and acquisitions, and the relentless pace of innovation create a high-stakes environment where timing is paramount. Brazikumab was a scientifically sound drug that, through no fault of its own molecular or clinical properties, simply ran out of time. Its legacy is that of a critical lesson in the myriad non-scientific risks that can ultimately define the success or failure of a new medicine.

Works cited

1. Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease, accessed October 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10731694/
2. EU Clinical Trials Register, accessed October 17, 2025, https://www.clinicaltrialsregister.eu/ctr-search/trial/2018-001605-93/GB
3. Brazikumab: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed October 17, 2025, https://go.drugbank.com/drugs/DB16115
4. Brazikumab - Wikipedia, accessed October 17, 2025, https://en.wikipedia.org/wiki/Brazikumab
5. brazikumab | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 17, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=9293
6. Brazikumab - AstraZeneca - AdisInsight - Springer, accessed October 17, 2025, https://adisinsight.springer.com/drugs/800031922
7. Brazikumab - Drug Targets, Indications, Patents - Patsnap Synapse, accessed October 17, 2025, https://synapse.patsnap.com/drug/5d5791b70c56414a89d4fdf88e131184
8. Brazikumab Overview - Creative Biolabs, accessed October 17, 2025, https://www.creativebiolabs.net/brazikumab-overview.htm
9. Use of Interleukin-23 Inhibitors for the Treatment of Inflammatory ..., accessed October 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11920014/
10. Update on brazikumab development programme - AstraZeneca, accessed October 17, 2025, https://www.astrazeneca.com/media-centre/press-releases/2023/update-on-brazikumab-development-programme.html
11. The Role of Brazikumab in Treating Inflammatory Bowel Diseases, accessed October 17, 2025, https://www.farbefirma.org/post/brazikumab-a-promising-therapy-for-inflammatory-bowel-disease
12. AstraZeneca (AZN) Discontinues Brazikumab Development - Nasdaq, accessed October 17, 2025, https://www.nasdaq.com/articles/astrazeneca-azn-discontinues-brazikumab-development
13. AstraZeneca recovery of global rights to brazikumab (MEDI2070) from Allergan completed, accessed October 17, 2025, https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-recovery-of-global-rights-to-brazikumab-medi2070-from-allergan-completed.html
14. An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease - AstraZeneca Clinical Trials, accessed October 17, 2025, https://www.astrazenecaclinicaltrials.com/study/D5271C00001/
15. Open-label Extension Study of Brazikumab in Crohn's Disease, accessed October 17, 2025, https://www.abbvieclinicaltrials.com/study/?id=D5271C00002
16. NCT03961815 | Open-label Extension Study of Brazikumab in Crohn's Disease | ClinicalTrials.gov, accessed October 17, 2025, https://clinicaltrials.gov/study/NCT03961815
17. NCT03616821 | Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis | ClinicalTrials.gov, accessed October 17, 2025, https://www.clinicaltrials.gov/study/NCT03616821
18. Open-label Extension Study of Brazikumab in Ulcerative Colitis - AstraZeneca Clinical Trials, accessed October 17, 2025, https://www.astrazenecaclinicaltrials.com/study/D5272C00002/
19. Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease - PubMed, accessed October 17, 2025, https://pubmed.ncbi.nlm.nih.gov/38124112/
20. (PDF) Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn's disease - ResearchGate, accessed October 17, 2025, https://www.researchgate.net/publication/376684748_Long-term_safety_of_brazikumab_in_the_open-label_period_of_a_randomized_phase_2a_study_of_patients_with_Crohn's_disease
21. NCT03759288 | An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease | ClinicalTrials.gov, accessed October 17, 2025, https://clinicaltrials.gov/study/NCT03759288
22. Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis - Expedition - AstraZeneca Clinical Trials, accessed October 17, 2025, https://www.astrazenecaclinicaltrials.com/study/D5272C00001/
23. AstraZeneca to recover the global rights to brazikumab (MEDI2070) from Allergan, accessed October 17, 2025, https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-to-recover-the-global-rights-to-brazikumab-medi2070-from-allergan-27012020.html
24. AstraZeneca acquires global rights to brazikumab following AbbVie's pending acquisition of Allergan - Pharmaceutical Technology, accessed October 17, 2025, https://www.pharmaceutical-technology.com/analyst-comment/brazikumab-allergan/
25. AstraZeneca abandons experimental bowel disease drug - BioPharma Dive, accessed October 17, 2025, https://www.biopharmadive.com/news/astrazeneca-brazikumab-ibd-discontinue-stop-il-23/651765/
26. Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants with Active, Moderate to Severe Crohn's Disease - AstraZeneca Clinical Trials, accessed October 17, 2025, https://www.astrazenecaclinicaltrials.com/study/D5170C00002/
27. NCT05033431 | Study to Evaluate the Pharmacokinetics (Movement of Drugs Within the Body), Safety and Tolerability of Brazikumab in Healthy Chinese and White Participants | ClinicalTrials.gov, accessed October 17, 2025, https://www.clinicaltrials.gov/study/NCT05033431
28. Brazikumab Completed Phase 1 Trials for Healthy Volunteers (HV, accessed October 17, 2025, https://go.drugbank.com/drugs/DB16115/clinical_trials?conditions=DBCOND0114743&phase=1&purpose=other&status=completed
29. Study to Evaluate the Pharmacokinetics (movement of drugs within ..., accessed October 17, 2025, https://www.astrazenecaclinicaltrials.com/study/D5271C00004/
30. Combining pharmacometric models with predictive and prognostic biomarkers for precision therapy in Crohn's disease: A case study of brazikumab - PubMed Central, accessed October 17, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10725267/
31. Allergan to offload IL-23 inhibitor brazikumab and Zenpep as part of AbbVie merger, accessed October 17, 2025, https://firstwordpharma.com/story/4938425
32. Allergan Launches Personalized Study Approach for Clinical Research Programs in Inflammatory Bowel Disease - AbbVie News Center, accessed October 17, 2025, https://news.abbvie.com/2018-10-05-Allergan-Launches-Personalized-Study-Approach-for-Clinical-Research-Programs-in-Inflammatory-Bowel-Disease
33. Analysis of Agreement Containing Consent Orders to Aid Public Comment - Federal Trade Commission, accessed October 17, 2025, https://www.ftc.gov/system/files/documents/cases/191_0169_abbvie_and_allergan_-_aapc.pdf
34. FTC Imposes Conditions on AbbVie Inc.'s Acquisition of Allergan plc, accessed October 17, 2025, https://www.ftc.gov/news-events/news/press-releases/2020/05/ftc-imposes-conditions-abbvie-incs-acquisition-allergan-plc
35. EMEA-001929-PIP01-16 - paediatric investigation plan - European Medicines Agency, accessed October 17, 2025, https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/emea-001929-pip01-16
36. NCT03616821 | Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis | ClinicalTrials.gov, accessed October 17, 2025, https://clinicaltrials.gov/study/NCT03616821
37. New safety warning for medicines used in arthritis and other inflammatory conditions, accessed October 17, 2025, https://www.tga.gov.au/safety/safety-alerts/new-safety-warning-medicines-used-arthritis-and-other-inflammatory-conditions
38. AstraZeneca drops Skyrizi rival after seeing R&D timeline spiral - Fierce Biotech, accessed October 17, 2025, https://www.fiercebiotech.com/biotech/astrazeneca-drops-skyrizi-rival-after-seeing-rd-timeline-spiral
39. Horizon scanning: new and future therapies in the management of inflammatory bowel disease | eGastroenterology, accessed October 17, 2025, https://egastroenterology.bmj.com/content/1/2/e100012